Core Viewpoint - Viatris reported quarterly earnings of $0.54 per share, missing the Zacks Consensus Estimate of $0.57 per share, and showing a decline from $0.61 per share a year ago, indicating an earnings surprise of -5.26% [1][2] Financial Performance - The company posted revenues of $3.53 billion for the quarter ended December 2024, missing the Zacks Consensus Estimate by 2.04%, and down from $3.84 billion year-over-year [2] - Over the last four quarters, Viatris has surpassed consensus EPS estimates two times and topped revenue estimates just once [2] Stock Performance - Viatris shares have declined approximately 9.7% since the beginning of the year, contrasting with the S&P 500's gain of 1.3% [3] - The current Zacks Rank for Viatris is 4 (Sell), indicating expected underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.63 on revenues of $3.58 billion, and for the current fiscal year, it is $2.57 on revenues of $14.25 billion [7] - The trend for estimate revisions ahead of the earnings release was unfavorable, which may impact future stock movements [6] Industry Context - The Medical Services industry, to which Viatris belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable industry outlook [8]
Viatris (VTRS) Q4 Earnings and Revenues Lag Estimates